Advertisement

Cancer and atrial fibrillation. Author's reply

  • Vincenzo Livio Malavasi
    Affiliations
    Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Modena, Italy
    Search for articles by this author
  • Marco Marietta
    Affiliations
    Hematology Division, University of Modena and Reggio Emilia, Policlinico di Modena, Modena, Italy
    Search for articles by this author
  • Gregory Y.H. Lip
    Affiliations
    Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK
    Search for articles by this author
  • Giuseppe Boriani
    Correspondence
    Corresponding author at: Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena Via del Pozzo, 71, 41124 Modena, Italy.
    Affiliations
    Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Modena, Italy
    Search for articles by this author
Published:January 18, 2019DOI:https://doi.org/10.1016/j.ejim.2019.01.002
      We appreciate the interest of Sorigue in our paper [
      • Malavasi V.L.
      • Fantecchi E.
      • Gianolio L.
      • Pesce F.
      • Longo G.
      • Marietta M.
      • et al.
      Atrial fibrillation in patients with active malignancy and use of anticoagulants: under-prescription but no adverse impact on all-cause mortality.
      ,
      • Sorigue M.
      On cancer and atrial fibrillation: nuances and limitations.
      ]. In his comments [
      • Sorigue M.
      On cancer and atrial fibrillation: nuances and limitations.
      ], he underlines several interesting points relevant to the management of atrial fibrillation (AF) in cancer patients.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Malavasi V.L.
        • Fantecchi E.
        • Gianolio L.
        • Pesce F.
        • Longo G.
        • Marietta M.
        • et al.
        Atrial fibrillation in patients with active malignancy and use of anticoagulants: under-prescription but no adverse impact on all-cause mortality.
        Eur J Intern Med. 2018 Oct 29; (pii: S0953–6205(18)30405–9. [Epub ahead of print])https://doi.org/10.1016/j.ejim.2018.10.012
        • Sorigue M.
        On cancer and atrial fibrillation: nuances and limitations.
        Eur J Intern Med. 2018; ([in press])
        • Russo V.
        • Bottino R.
        • Rago A.
        • Micco P.D.
        • D'Onofrio A.
        • Liccardo B.
        • et al.
        Atrial fibrillation and malignancy: the clinical performance of non-vitamin K oral anticoagulants-A systematic review.
        Semin Thromb Hemost. 2018, Aug 17; ([Epub ahead of print])https://doi.org/10.1055/s-0038-1661386
        • Buza V.
        • Rajagopalan B.
        • Curtis A.B.
        Cancer Treatment-Induced Arrhythmias: focus on Chemotherapy and Targeted Therapies.
        Circ Arrhythm Electrophysiol. 2017; 10 ([pii: e005443])
        • Boriani G.
        • Corradini P.
        • Cuneo A.
        • Falanga A.
        • Foa R.
        • Gaidano G.
        • et al.
        Practical management of ibrutinib in the real life: focus on atrial fibrillation and bleeding.
        Hematological oncology. 2018 Oct; 36: 624-632
        • Kaifie A.
        • Kirschner M.
        • Wolf D.
        • Maintz C.
        • Hänel M.
        • Gattermann N.
        • et al.
        Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry.
        J Hematol Oncol. 2016; 9: 18
        • Lane D.A.
        • Aguinaga L.
        • Blomström-Lundqvist C.
        • Boriani G.
        • Dan G.A.
        • Hills M.T.
        • et al.
        Cardiac tachyarrhythmias and patient values and preferences for their management: the European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE).
        Europace. 2015; 17: 1747-1769
        • Marijon E.
        • Le Heuzey J.Y.
        • Connolly S.
        • Yang S.
        • Pogue J.
        • Brueckmann M.
        • et al.
        Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study.
        Circulation. 2013; 128: 2192-2201
        • Shah S.
        • Norby F.L.
        • Datta Y.H.
        • Lutsey P.L.
        • MacLehose R.F.
        • Chen L.Y.
        • et al.
        Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation.
        Blood advances. 2018; 2: 200-209
        • Patell R.
        • Gutierrez A.
        • Rybicki L.
        • Khorana A.A.
        Usefulness of CHADS2 and CHA2DS2-VASc scores for stroke prediction in patients with cancer and atrial fibrillation.
        Am J Cardiol. 2017; 120: 2182-2186
        • Vedovati M.C.
        • Giustozzi M.
        • Verdecchia P.
        • Pierpaoli L.
        • Conti S.
        • Verso M.
        • et al.
        Patients with cancer and atrial fibrillation treated with doacs: a prospective cohort study.
        Int J Cardiol. 2018; 269: 152-157
        • Sorigue M.
        • Sarrate E.
        • Franch-Sarto M.
        • Sancho J.M.
        • Orna E.
        Risk of cardioembolic stroke in patients with cancer and atrial fibrillation.
        Am J Cardiol. 2018; 121: 1656-1657
        • Raskob G.E.
        • van Es N.
        • Verhamme P.
        • Carrier M.
        • Di Nisio M.
        • Garcia D.
        • et al.
        Edoxaban for the treatment of cancer-associated venous thromboembolism.
        N Engl J Med. 2018; 378: 615-624
        • Imberti D.
        • Cimminiello C.
        • Di Nisio M.
        • Marietta M.
        • Polo Friz H.
        • Ageno W.
        Antithrombotic therapy for venous thromboembolism in patients with cancer: expert guidance.
        Expert Opin Pharmacother. 2018 Aug; 19: 1177-1185
        • Kraaijpoel N.
        Carrier M.
        How I treat cancer-associated venous thromboembolism, Blood2018 Nov 26 ([Epub ahead of print])
        • Lutsey P.L.
        • Norby F.L.
        • Alonso A.
        • Cushman M.
        • Chen L.Y.
        • Michos E.D.
        • et al.
        Atrial fibrillation and venous thromboembolism: evidence of bidirectionality in the atherosclerosis risk in communities study.
        J Thromb Haemost. 2018; 16: 670-679
        • Hald E.M.
        • Enga K.F.
        • Løchen M.L.
        • Mathiesen E.B.
        • Njølstad I.
        • Wilsgaard T.
        • et al.
        Venous thromboembolism increases the risk of atrial fibrillation: the Tromso study.
        J Am Heart Assoc. 2014; 3e000483
        • Enga K.F.
        • Rye-Holmboe I.
        • Hald E.M.
        • Løchen M.L.
        • Mathiesen E.B.
        • Njølstad I.
        • et al.
        Atrial fibrillation and future risk of venous thromboembolism:the Tromsø study.
        J Thromb Haemost. 2015; 13: 10-16
        • Lubitz S.A.
        • Yin X.
        • Rienstra M.
        • Schnabel R.B.
        • Walkey A.J.
        • Magnani J.W.
        • et al.
        Long-term outcomes of secondary atrial fibrillation in the community: the Framingham Heart Study.
        Circulation. 2015; 131: 1648-1655
        • Boriani G.
        • Fauchier L.
        • Aguinaga L.
        • Beattie J.M.
        • Blomstrom Lundqvist C.
        • Cohen A.
        • et al.
        European Heart Rhythm Association (EHRA) consensus document on management of arrhythmias and cardiac electronic devices in the critically ill and post-surgery patient, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa (CASSA), and Latin American Heart Rhythm Society (LAHRS).
        Europace. 2019; 21 (Jan 1): 7-8https://doi.org/10.1093/europace/euy110

      Linked Article

      • On cancer and atrial fibrillation: Nuances and limitations
        European Journal of Internal MedicineVol. 62
        • Preview
          In a recent study, Malavasi et al. [1] describe the prevalence and predictive factors for anticoagulant use in a cohort of patients with atrial fibrillation (AF) and cancer admitted into an oncology unit. Their main findings are that 1) 8.4% of the more than 4500 patients had AF. 2) that only 41% of patients received full-dose anticoagulation and, of those, almost 80% received low molecular weight heparin (LMWH) while an additional 35% received prophylactic-dose LMWH. 3) that anticoagulant use was not predicted by either cancer type or stage or CHA2DS2VASC and 4) that the use of anticoagulants did not impact overall survival.
        • Full-Text
        • PDF